Alto Neuroscience, INC 10-Q quarterly reports

Alto Neuroscience reported a net loss of $27.6 million for Q2 2026, but bolstered its cash position with a $94.6 million offering and detailed progress across its seven clinical-stage assets.

Alto Neuroscience reports a significant increase in R&D expenses for Q1 2026, driven by advancements in its ALTO-101 and ALTO-207 programs, alongside substantial capital raised through private placements.

Alto Neuroscience reports Q3 2025 results, highlighting pipeline advancements for ALTO-101 and ALTO-207, and a $49.9 million private placement extending its cash runway into 2028.

Alto Neuroscience reported increased net losses and cash burn in Q2 2025, but extended its cash runway into 2028 through new financing and operational efficiencies, while advancing multiple clinical programs and acquiring new assets.

Alto Neuroscience reports a net loss of $15.2 million for Q1 2025 and provides updates on its clinical-stage assets targeting psychiatric disorders.

Alto Neuroscience's third quarter report reveals a net loss of $16.8 million and the failure of its Phase 2b trial of ALTO-100 in MDD to meet its primary endpoint, while highlighting ongoing clinical trials and a new convertible loan agreement.

Alto Neuroscience, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Alto Neuroscience's first quarter 2024 results show increased spending on research and development, offset by proceeds from a recent IPO.